MedTrace Logo

Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass

NCT04296474 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2022-09-21

No results posted yet for this study

Summary

52 patients that had previously participated in the RDBPC study of intralymphatic immunotherapy (ILIT) with 2 concomitant allergens, birch and grass, with NCT02423707, were eligible for an open follow up 5-6 years after treatment.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

ALK Alutard 5-grasses and birch

Intralymphatic injections

DRUG

ALK Diluent

intralymphatic injections

Sponsors & Collaborators

  • Lars Olaf Cardell

    lead OTHER

Principal Investigators

  • Lars Olaf Cardell, Professor · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-15
Primary Completion
2022-06-20
Completion
2022-07-01

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04296474 on ClinicalTrials.gov